Clinical trial NCT05618561: EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)
Official title: EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test Clinical Performance Study
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: SARS-CoV-2 Infection
Keywords: covid19
Lead sponsor: AnteoTech Ltd
Sponsor class: INDUSTRY
First posted: 2022-11-16
Enrollment: 599
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The entire population over 12 years of age that met the inclusion criteria and none of the exclusion criteria. Positive subjects must present COVID19 symptoms. In the case of negative subjects, one part must be hospitalized (for any reason) and the other part must have respiratory symptoms.

Brief summary: Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2 infection based on a qualitative approach. RAD tests detect the viral antigen by the immobilized coated SARS-CoV-2 antibody placed on the device. The results of these tests are available in a short time, reducing the workload in diagnostic hospitals and laboratories and improving the turn-around time.

EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test is an in vitro Diagnostic (IVD) medical device intended to be used for the qualitative detection of SARS-CoV-2 nucleocapsid antigen. The result from this IVD test identifies the presence or absence of the SARS-CoV-2 antigen as an aid for the diagnosis of COVID-19 infection.

Detailed description: The EuGeni SARS-CoV-2 Antigen (Ag) Rapid Detection Test (RDT) is a test strip based on lateral flow technology which utilizes nanoparticles, doped with europium, as the fluorescence reporter system. The test strip is housed in a cassette which is read by the EuGeni AX-2X-S Reader, a portable instrument that reads EuGeni fluorescent lateral flow tests.

The test line contains an immobilized monoclonal mouse antibody to capture SARS-CoV-2 antigen and the control line contains an immobilized control anti-mouse antibody.

The test sample is added to the sample well of the test cassette and then reconstitutes the dried europium nanoparticle antibody conjugate from the conjugate pad. The sample flows along the test strip by capillary action.

If the sample contains SARS-CoV-2 antigen, it binds to the antibody-labelled europium nanoparticle. When the sample flows past the test line, the europium bound antigen is captured by the second anti-SARS-CoV-2 antibody immobilized on the test line. A fluorescent signal detected by the EuGeni AX-2X-S Reader at this test line indicates that the specimen is SARS-CoV-2 antigen Positive.

If the sample does not contain SARS-CoV-2 antigen, the europium-labelled anti-antigen antibody will not bind to the test line. This indicates that the specimen is SARS-CoV-2 antigen Negative.

The sample continues to flow along the strip and when it passes over the control line, antibody-labelled europium nanoparticles are captured by the immobilized anti-mouse antibody. The control line must be detected by the EuGeni AX-2X-S Reader for the test to be valid. If the control line is not detected, the test is considered invalid and must be repeated using another test cassette.

Eligibility criteria: Inclusion Criteria:

1. Specimens from subjects over 12 years old agreeing to participate in the study and with a legal representative able to provide informed consent, OR;
2. Specimens from subjects over 18 years old able to provide informed consent.
3. Specimens collected with nasopharyngeal swabs, OR;
4. Combined nasal mid-turbinate and throat specimen collection.

Exclusion Criteria:

1. Specimens and testing methods that are not deemed to be in line with gold-standard RT-PCR standards.
2. Specimens stored for over 2 hours at 2-8 ºC temperature between collection and testing with EuGeni SARS-CoV-2 Ag RDT.
3. Specimens stored for over 5 days at -20ºC between collection and testing with RT-PCR.
4. Specimens stored for over 24h at 4ºC between collection and testing with RT-PCR.
5. Contamination and/or deterioration of the specimen which, in the opinion of the investigator, may affect its handling and/or analysis.
6. The subject is deemed unsuitable to participate in the study by the investigator.

Primary outcomes:
measure: Diagnostic sensitivity and specificity in terms of true positive results and true negative results between the kit under investigation and the gold-standard PCR
timeFrame: Through study completion, an average of 4 months
Secondary outcomes:
measure: The sensitivity and the specificity values between the two collection methods, nasal and nasopharyngeal.
timeFrame: Through study completion, an average of 4 months
Other outcomes:
Locations:
city: Split
country: Croatia
facility: Institut Virion
city: Athens
country: Greece
facility: Laiko General Hospital
city: Zaragoza
country: Spain
facility: Centro de Salud Fuentes Norte
state: Aragón
city: Zaragoza
country: Spain
facility: Centro de Salud Torre Ramona
state: Aragón
city: A Coruña
country: Spain
facility: Hospital Universitario de A Coruña (CHUAC)
state: Galicia
Study officials:
affiliation: C.S. Fuentes Norte
name: M. Antonia Sánchez Calavera
role: PRINCIPAL_INVESTIGATOR
References: